WallStSmart

Healthcare Triangle Inc (HCTI)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 360388% more annual revenue ($72.25B vs $20.04M). LLY leads profitability with a 35.0% profit margin vs -69.7%. LLY earns a higher WallStSmart Score of 76/100 (B+).

HCTI

Hold

41

out of 100

Grade: D

Growth: 5.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -2.84

LLY

Strong Buy

76

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 4.3Quality: 6.0
Piotroski: 6/9Altman Z: 2.06

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCTI3 strengths · Avg: 9.7/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
166.1%10/10

Revenue surging 166.1% year-over-year

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$1.02T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
78.8%10/10

Every $100 of equity generates 79 in profit

Profit MarginProfitability
35.0%10/10

Keeps 35 of every $100 in revenue as profit

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
55.5%10/10

Revenue surging 55.5% year-over-year

EPS GrowthGrowth
169.9%10/10

Earnings expanding 169.9% YoY

Areas to Watch

HCTI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.53M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-26.5%2/10

ROE of -26.5% — below average capital efficiency

LLY4 concerns · Avg: 3.3/10
PEG RatioValuation
1.614/10

Expensive relative to growth rate

P/E RatioValuation
39.6x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.623/10

Elevated debt levels

Price/BookValuation
33.8x2/10

Trading at 33.8x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : HCTI

The strongest argument for HCTI centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 166.1% demonstrates continued momentum.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.

Bear Case : HCTI

The primary concerns for HCTI are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : LLY

The primary concerns for LLY are PEG Ratio, P/E Ratio, Debt/Equity. Debt-to-equity of 1.62 is elevated, increasing financial risk.

Key Dynamics to Monitor

HCTI profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.

HCTI carries more volatility with a beta of 1.12 — expect wider price swings.

HCTI is growing revenue faster at 166.1% — sustainability is the question.

LLY generates stronger free cash flow (7.8B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (76/100 vs 41/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Healthcare Triangle Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Healthcare Triangle, Inc. is a healthcare information technology company. The company is headquartered in Pleasanton, California.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?